BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	1.5M 1.71M 1.71M 1.4M 1.29M 2.41M 164M 2.47M 16.62M 6.5M 81M 6.42M 6.28M 280M	P/E 2023	-0.29x	P/E 2024	-0.28x
Enterprise Value	28.84M 32.82M 32.82M 26.92M 24.7M 46.24M 3.14B 47.38M 319M 125M 1.56B 123M 121M 5.38B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

28/10/25	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/10/25	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
29/09/25	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
28/10/24	BioSenic S.A. Announces Executive Changes	CI
30/09/24	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/09/24	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
17/09/24	BioSenic Deputy CEO Steps Down	MT
17/09/24	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
14/08/24	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
14/08/24	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
13/08/24	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
18/07/24	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
05/07/24	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25/09/25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
29/08/25	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
04/08/25	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
01/07/25	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

Bone Therapeutics SA Stock Euronext Bruxelles

Stocks

BOTHE

BE0974280126

Pharmaceuticals

Valuation: Bone Therapeutics SA

Latest news : Bone Therapeutics SA

Analysts' recommendations: Bone Therapeutics SA

Press Releases: Bone Therapeutics SA

News in other languages: Bone Therapeutics SA

Managers and Directors: Bone Therapeutics SA

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	01/01/2022
Eric Halioua CHM	Chairman	-	01/09/2025
Virginie Miath BRD	Director/Board Member	-	29/01/2026

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.87%	+4.04%	+58.60%	+163.92%	1,079B
JOHNSON & JOHNSON	-0.45%	+3.87%	+57.95%	+52.18%	640B
ABBVIE INC.	+0.04%	+3.95%	+37.69%	+74.54%	465B
ROCHE HOLDING AG	-1.02%	+3.12%	+38.83%	+33.19%	353B
NOVARTIS AG	-0.70%	+1.44%	+36.29%	+42.20%	301B
ASTRAZENECA PLC	-1.02%	+3.01%	+13.67%	+16.84%	271B
NOVO NORDISK A/S	-0.70%	+5.17%	+3.65%	-38.32%	228B
AMGEN INC.	-1.39%	+5.90%	+27.70%	+64.00%	209B
GILEAD SCIENCES, INC.	-1.18%	+1.83%	+16.20%	+72.69%	165B
Average	-0.66%	+4.83%	+32.29%	+53.47%	412.19B
Weighted average by Cap.	-0.62%	+4.86%	+41.90%	+78.32%

	2023	2024
Net sales	336K 382K 382K 314K 288K 539K 36.63M 552K 3.72M 1.45M 18.12M 1.44M 1.4M 62.65M	102K 116K 116K 95.21K 87.38K 164K 11.12M 168K 1.13M 442K 5.5M 436K 426K 19.02M
Net income	-28.78M -32.75M -32.75M -26.86M -24.65M -46.15M -3.14B -47.29M -319M -125M -1.55B -123M -120M -5.37B	-4.77M -5.43M -5.43M -4.45M -4.08M -7.65M -520M -7.83M -52.78M -20.64M -257M -20.37M -19.93M -889M
Net Debt	28.04M 31.91M 31.91M 26.17M 24.02M 44.97M 3.06B 46.07M 310M 121M 1.51B 120M 117M 5.23B	27.34M 31.11M 31.11M 25.52M 23.42M 43.84M 2.98B 44.92M 303M 118M 1.47B 117M 114M 5.1B

End-of-day quote Euronext Bruxelles Other stock markets
-	-